WO2020259724A3 - 一种吡唑酮并嘧啶类化合物、其制备方法及应用 - Google Patents

一种吡唑酮并嘧啶类化合物、其制备方法及应用 Download PDF

Info

Publication number
WO2020259724A3
WO2020259724A3 PCT/CN2020/112034 CN2020112034W WO2020259724A3 WO 2020259724 A3 WO2020259724 A3 WO 2020259724A3 CN 2020112034 W CN2020112034 W CN 2020112034W WO 2020259724 A3 WO2020259724 A3 WO 2020259724A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazolone
preparation
pyrimidine compound
use therefor
compound
Prior art date
Application number
PCT/CN2020/112034
Other languages
English (en)
French (fr)
Other versions
WO2020259724A2 (zh
Inventor
王倩
霍国永
夏广新
楼江松
舒思杰
葛辉
张霖
石辰
张智慧
毛煜
张冰宾
余建鑫
刘彦君
Original Assignee
上海医药集团股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2021578137A priority Critical patent/JP2022539460A/ja
Priority to CA3145348A priority patent/CA3145348A1/en
Priority to EP20831960.8A priority patent/EP4008719A4/en
Priority to AU2020304472A priority patent/AU2020304472A1/en
Priority to US17/623,001 priority patent/US20220324868A1/en
Priority to MX2022000199A priority patent/MX2022000199A/es
Application filed by 上海医药集团股份有限公司 filed Critical 上海医药集团股份有限公司
Priority to BR112021026620A priority patent/BR112021026620A2/pt
Priority to KR1020227002020A priority patent/KR20230046270A/ko
Publication of WO2020259724A2 publication Critical patent/WO2020259724A2/zh
Publication of WO2020259724A3 publication Critical patent/WO2020259724A3/zh
Priority to IL289395A priority patent/IL289395A/en
Priority to CONC2022/0000751A priority patent/CO2022000751A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

本发明公开了一种吡唑酮并嘧啶类化合物、其制备方法及应用。本发明提供了一种如式(I)所示的吡唑酮并嘧啶类化合物，该类化合物对WEE1激酶的抑制活性较佳。
PCT/CN2020/112034 2019-06-28 2020-08-28 一种吡唑酮并嘧啶类化合物、其制备方法及应用 WO2020259724A2 (zh)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA3145348A CA3145348A1 (en) 2019-06-28 2020-08-28 Pyrazolone and pyrimidine compound, and preparation method and use therefor
EP20831960.8A EP4008719A4 (en) 2019-06-28 2020-08-28 PYRAZOLON AND PYRIMIDINE COMPOUND, PROCESS FOR THEIR PREPARATION AND USE
AU2020304472A AU2020304472A1 (en) 2019-06-28 2020-08-28 Pyrazolone and pyrimidine compound, and preparation method and use therefor
US17/623,001 US20220324868A1 (en) 2019-06-28 2020-08-28 Pyrazolone-Fused Pyrimidine Compound, and Preparation Method and Use Therefor
MX2022000199A MX2022000199A (es) 2019-06-28 2020-08-28 Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo.
JP2021578137A JP2022539460A (ja) 2019-06-28 2020-08-28 ピラゾロン縮合ピリミジン化合物、その製造方法及び使用
BR112021026620A BR112021026620A2 (pt) 2019-06-28 2020-08-28 Composto de pirazolona e pirimidina, e método de preparação e uso para o mesmo
KR1020227002020A KR20230046270A (ko) 2019-06-28 2020-08-28 피라졸론 및 피리미딘 화합물, 및 그의 제조 방법 및 용도
IL289395A IL289395A (en) 2019-06-28 2021-12-26 Pyrazolone and pyrimidine compounds, preparation method and their use
CONC2022/0000751A CO2022000751A2 (es) 2019-06-28 2022-01-27 Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910578299.1 2019-06-28
CN201910578299 2019-06-28

Publications (2)

Publication Number Publication Date
WO2020259724A2 WO2020259724A2 (zh) 2020-12-30
WO2020259724A3 true WO2020259724A3 (zh) 2021-02-18

Family

ID=73889014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/112034 WO2020259724A2 (zh) 2019-06-28 2020-08-28 一种吡唑酮并嘧啶类化合物、其制备方法及应用

Country Status (13)

Country Link
US (1) US20220324868A1 (zh)
EP (1) EP4008719A4 (zh)
JP (1) JP2022539460A (zh)
KR (1) KR20230046270A (zh)
CN (1) CN112142748B (zh)
AU (1) AU2020304472A1 (zh)
BR (1) BR112021026620A2 (zh)
CA (1) CA3145348A1 (zh)
CL (1) CL2021003498A1 (zh)
CO (1) CO2022000751A2 (zh)
IL (1) IL289395A (zh)
MX (1) MX2022000199A (zh)
WO (1) WO2020259724A2 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276802B2 (en) 2018-03-09 2023-09-01 Recurium Ip Holdings Llc Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones
CN115867551A (zh) * 2020-05-15 2023-03-28 里科瑞尔姆Ip控股有限责任公司 单一疗法和组合疗法
CN114591334B (zh) * 2020-12-04 2023-10-20 山东轩竹医药科技有限公司 二氢吡唑并嘧啶酮衍生物
WO2022251224A1 (en) * 2021-05-28 2022-12-01 Recurium Ip Holdings, Llc Wee1 inhibitors and methods for treating cancer
CN117751122A (zh) * 2021-08-11 2024-03-22 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2023083194A1 (zh) * 2021-11-09 2023-05-19 杭州格博生物医药有限公司 Wee1蛋白激酶降解剂及其用途
WO2023193789A1 (en) * 2022-04-08 2023-10-12 Beijing Neox Biotech Limited Wee1 degrading compounds

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075629A2 (en) * 2015-11-01 2017-05-04 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
WO2018133829A1 (zh) * 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
WO2019028008A1 (en) * 2017-08-01 2019-02-07 Zeno Royalties & Milestones, LLC 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019074979A1 (en) * 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN109810111A (zh) * 2017-11-20 2019-05-28 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
WO2019173082A1 (en) * 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005534681A (ja) 2002-07-15 2005-11-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としてのトキソフラビンの３−フラニル類似物
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
JP2010522186A (ja) 2007-03-20 2010-07-01 スミスクライン ビーチャム コーポレーション 化合物
MX2009010047A (es) 2007-03-20 2009-12-04 Smithkline Beecham Corp Compuestos quimicos.
CA2745970A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
WO2010098367A1 (en) 2009-02-25 2010-09-02 Banyu Pharmaceutical Co.,Ltd. Pyrimidopyrimidoindazole derivative

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075629A2 (en) * 2015-11-01 2017-05-04 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
WO2018133829A1 (zh) * 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
WO2019028008A1 (en) * 2017-08-01 2019-02-07 Zeno Royalties & Milestones, LLC 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019074979A1 (en) * 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN109810111A (zh) * 2017-11-20 2019-05-28 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
WO2019173082A1 (en) * 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Also Published As

Publication number Publication date
AU2020304472A1 (en) 2022-03-03
CL2021003498A1 (es) 2022-08-19
CO2022000751A2 (es) 2022-04-29
CN112142748A (zh) 2020-12-29
EP4008719A4 (en) 2023-03-22
BR112021026620A2 (pt) 2022-06-07
IL289395A (en) 2022-02-01
WO2020259724A2 (zh) 2020-12-30
KR20230046270A (ko) 2023-04-05
CN112142748B (zh) 2023-07-04
US20220324868A1 (en) 2022-10-13
EP4008719A2 (en) 2022-06-08
CA3145348A1 (en) 2020-12-30
JP2022539460A (ja) 2022-09-09
MX2022000199A (es) 2022-09-29

Similar Documents

Publication Publication Date Title
WO2020259724A3 (zh) 一种吡唑酮并嘧啶类化合物、其制备方法及应用
EP3972967A4 (en) HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THEIR USES
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
EP4077311A4 (en) HETEROCYCLIC COMPOUNDS, THEIR PREPARATION PROCESSES AND THEIR USES
EP3980010A4 (en) 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
WO2007023382A3 (en) Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2007027238A3 (en) Jak kinase inhibitors and their uses
EP3572413A4 (en) 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE DERIVATIVE USED AS A WEE1 INHIBITOR
TN2018000087A1 (en) New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
AU2020317609A8 (en) Novel heteroaryl-triazole compounds as pesticides
MX2021004659A (es) Derivados de aminopirimidina/pirazina como inhibidores de ctps1.
EP3967694A4 (en) TRI-SUBSTITUTED PYRIMIDINE COMPOUND IN POSITIONS 2, 4, 6 USED AS ATR KINASE INHIBITOR
EP4028393A4 (en) 3,5-DISUBSTITUTED PYRAZOLE COMPOUNDS AS KINAS INHIBITORS AND THEIR USES
EP3935037A4 (en) USE OF 8,9-DIHYDROCANNABIDIOL COMPOUNDS
EP3936509A4 (en) FGFR4 KINASE INHIBITOR, METHOD FOR PREPARATION AND USE
MX2022000243A (es) Nuevos compuestos heterociclicos.
MX2021015572A (es) Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones.
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
EP4046999A4 (en) AMINOPYRIMIDINE COMPOUND USED AS TRIPLE INHIBITOR OF CDK2/4/6
EP3933044A4 (en) CONVENIENT ENZYME SYNTHESIS OF 3', 3'-CGAMP
EP4011865A4 (en) BRIDGED HETEROCYCLYL SUBSTITUTED PYRIMIDINE COMPOUND, METHOD FOR PREPARATION AND PHARMACEUTICAL USE
AU2019408336A8 (en) Phenylpyrrolidine compound and use thereof
EP4010813A4 (en) SPREAD TABLE TRANSFORMATION
EP3966204A4 (en) SUBSTITUTED 1-AMINO-1H-IMIDAZOLE-5-CARBOXAMIDE AS BRUTON TYROSINE KINASE INHIBITORS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20831960

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3145348

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021578137

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021026620

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020831960

Country of ref document: EP

Effective date: 20220128

ENP Entry into the national phase

Ref document number: 2020304472

Country of ref document: AU

Date of ref document: 20200828

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112021026620

Country of ref document: BR

Free format text: APRESENTE O RELATORIO DESCRITIVO.

ENP Entry into the national phase

Ref document number: 112021026620

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20211228